Full Press Release Details
Annovis Bio Receives FDA Approval to Transition to New Crystal
MALVERN, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- via IBN - Annovis
Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative
therapies for neurodegenerative disorders such as Alzheimer's Disease (AD) and Parkinson's Disease (PD), announced today
that it has received approval from the U.S. Food and Drug Administration (FDA) to transition to a new solid form of buntanetap in future
In June 2024, Annovis announced the filing of a composition of matter
patent for the new crystal form of buntanetap and a provisional patent for the manufacturing process of this new form. The Company conducted
comprehensive bridge studies in various solvents and in animals, comparing the old semi-crystalline form with the new crystalline form
of buntanetap. Additionally, Annovis developed an innovative large-scale manufacturing process for the new form. This comprehensive data
was submitted to the FDA for review.
The FDA has now approved the continuation of buntanetap's development
using the new crystal form. This positive response allows Annovis to conduct a comparative study between the old and new forms of buntanetap
in a small, single-dose, bioavailability study in humans as part of the transition process.
Buntanetap (formerly known as Posiphen or ANVS401) targets neurodegeneration
by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This improves synaptic
transmission, axonal transport, and reduces neuroinflammation. Dysregulation of these pathways has been shown to cause nerve cell degeneration
and ultimately nerve cell death. By targeting these pathways, buntanetap has the potential to reverse neurodegeneration in Alzheimer's,
Parkinson's, and other neurodegenerative diseases, thereby aiming to restore brain function and improve the quality of life for
About Annovis Bio, Inc.
Headquartered in Malvern, Pennsylvania, Annovis Bio Inc. is dedicated
to addressing neurodegeneration in diseases such as AD and PD. The company's innovative approach targets multiple neurotoxic proteins,
aiming to restore brain function and improve the quality of life for patients. For more information, visit www.annovisbio.com
press releases and industry updates by registering for Email Alerts at https://www.Annovisbio.com/email-alerts.
Forward-Looking Statements
This press release contains "forward-looking" statements
within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These statements include, but are not limited to, the Company's plans related to clinical trials. Forward-looking statements
are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ
materially from those projected. Such risks and uncertainties include, but are not limited to, those related to patient enrollment, the
effectiveness of Buntanetap, and the timing, effectiveness, and anticipated results of the Company's clinical trials evaluating the efficacy,
safety, and tolerability of Buntanetap. Additional risk factors are detailed in the Company's periodic filings with the SEC, including
those listed in the "Risk Factors" section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All
forward-looking statements in this press release are based on information available to the Company as of the date of this release. The
Company expressly disclaims any obligation to update or revise its forward-looking statements, whether as a result of new information,
future events, or otherwise, except as required by law.
101 Lindenwood Drive
InvestorBrandNetwork (IBN)